Biovista sponsors the 2009 Notch Meeting

September 2, 2009Events

Athens, GR, September 2nd, 2009 — Biovista Inc. is pleased to announce its sponsoring of the international 2009 Notch Meeting to be held in Athens, Greece, from September 27th to October 1st, 2009. The Notch Meeting is a biennial event on general Notch research that aims to reflect the diversity of Notch research and bring together researchers … Read More

Biovista Inc. announces positive efficacy results in a pre-clinical trial of its BVA-601 drug for Epilepsy

June 23, 2009Press Releases

 CHARLOTTESVILLE, Virginia, June 23 /PRNewswire/ — Biovista Inc. today announced that BVA-601, its small-molecule drug targeting epilepsy, has shown positive results in the Kainic acid murine model of temporal lobe epilepsy. BVA-601, an existing drug that Biovista repositioned in epilepsy, exhibits both anti-epileptic and neuroprotective activity. In this pre-clinical trial, BVA-601 induced a statistically significant … Read More

Biovista Inc. announces positive efficacy results in a pre-clinical trial of BVA-101 for Multiple Sclerosis

April 2, 2009Press Releases

CHARLOTTESVILLE, Virginia, April 2 /PRNewswire/ — Biovista Inc. today announced that BVA-101, its drug targeting Multiple Sclerosis (MS), has shown significant positive results in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) murine model of MS. BVA-101, an existing drug that Biovista repositioned in MS and is aimed at neuroprotection, was shown to have both efficacy in … Read More